Released on = December 5, 2005, 9:01 am

Press Release Author = Jonathan Jordan

Industry = Biotech

Press Release Summary = Educational and advocacy group to promote the advancement
and understanding of personalized medicine

Press Release Body =

FOR IMMEDIATE RELEASE


Research Triangle Park, North Carolina - December 5th 2005 - Gentris Corporation, a
leading global provider of applied clinical pharmacogenomic services and diagnostic
product solutions, today announced that the company has joined the Personalized
Medicine Coalition (PMC).

The PMC was founded in 2003 by more than 20 leading pharmaceutical, biotechnology,
diagnostics and information technology companies, along with major academic centers
and governmental agencies. It is an independent, non-profit group dedicated to
advancing the understanding and adoption of personalized medicine concepts and
products for the ultimate benefit of patients. The Coalition seeks to promote
discussion and understanding that will lead to the development of sound public
policy on matters that affect the realization of personalized medicine.

"The Coalition brings together leaders from every sector involved in personalized
medicine. Together we will educate and explore issues that may require new or
revised public policy," commented Michael Murphy, President and CEO of Gentris. "We
are excited to be a part of a group that will have a profound effect on the medical
treatments that are currently used, and those still to be discovered."

Gentris executives are established thought leaders in the field of pharmacogenomics
and other important issues surrounding its applications including regulatory,
informed consent and patient confidentiality matters, In addition to conducting
gene-based clinical trials, Gentris provides consultation on these topics to several
participating members of the Pharmacogenomics Working Group. Gentris works with
numerous industry groups that are developing guidelines for the adoption of
pharmacogenomics in the clinical laboratory setting including the American
Association for Clinical Chemistry (AACC). Gentris executives frequently
participate in high profile meetings such as the Secretary's Advisory Committee on
Genetics, Health and Society as well as educational forums aimed at helping FDA
reviewers understand the possibilities and limitations of clinical pharmacogenomics.


Edward Abrahams, Executive Director of the PMC, sees Gentris as an integral member
of the Coalition whose mission it is to advance personalized medicine in the public
arena. "Gentris' leadership in promoting pharmacogenomics can provide invaluable
guidance and experience to our members and our mission," commented Abrahams.

# # #

About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic
services and diagnostic product solutions. As pioneers in the field of
pharmacogenomics, Gentris helps pharmaceutical companies and clinical research
organizations effectively integrate pharmacogenomics into their drug development
programs to deliver safer, more effective compounds to the market sooner. Gentris is
developing diagnostic test kits and validated reference controls that will bring the
promise of personalized medicine to physicians and patients, which will enhance
patient management, improve patients\' response to therapy and revolutionize medicine
through pharmacogenomics. For additional information, please visit
http://www.gentris.com.

About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC) is an independent, non-profit group that
works to advance the understanding and adoption of personalized medicine for the
ultimate benefit of patients. Our diverse members work together to educate opinion
leaders and the public about the issues that will shape how personalized medicine
develops - and how quickly all of us can benefit from it. Please visit the PMC at
www.personalizedmedicinecoalition.org .




Web Site = http://gentris.com

Contact Details = Jonathan Jordan
919 Marketing/919.557.7890
jjordan@919marketing.com